Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1b/2 study of niraparib-based combination therapies in metastatic castration-resistant prostate cancer
MOH_2018-06-11_002285Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of niraparib, dostarlimab, abiraterone and prednisone in prostate cancer (PCa) and metastatic castration-resistant prostate cancer (mCRPC) (3 arms), sponsored by Janssen Pharmaceutical. Started Feb 2018; status: completed.
02
Drugs
niraparibdostarlimababirateroneprednisone
03
Conditions
prostate cancer (PCa)metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2018-06-11_002285.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-06-11_002285.